Article Text

Download PDFPDF
289 Borderline ovarian tumors, 10 years of experience in a single-center
  1. Safa Jouini,
  2. Ines Ben Safta,
  3. Sarra Ben Ltaief,
  4. Ines Zemni and
  5. Tarek Ben Dhiab
  1. Salah Azaiez institute, Tunis, Tunisia


Introduction/Background A borderline tumor of the ovary (BOT) is an epithelial tumor with a low growth rate and a low potential to invade or metastasize. Accurate diagnosis and staging of borderline tumors have essential prognostic and management implications.

Methodology All borderline ovarian tumors registered in the Pathology Department of Salah Azaiez Institute from 2010–2022 were identified.

Results The average age of our patients was 43.4 years old, with limits varying between 21 and 65. Most BOTs were serous tumors (75%), followed by mucinous tumors (18%). The endometrioid type was seen in four cases.

The cases were divided into 38 cases of pure MBT, 16 cases with intraepithelial carcinoma, and 6 cases associating an intraepithelial carcinoma with micro invasion. Most cases were classified as FIGO I, and only two were FIGO III. Fourteen patients received conservative treatment, and 32 received radical treatment. The treatment was not specified in 3 patients. The follow-up was good in the majority of cases. Only one patient had a contralateral recurrence after a follow-up period of 3 years. There was no association between the risk of recurrence and risk factors such as age, gestation, hormonal contraception, hormonal status, FIGO stage, presence of pseudomyxoma peritonei, intraepithelial carcinoma, and micro invasion.

Conclusion The majority of patients with BOTs are frequently diagnosed during their reproductive age. For these patients, therapeutic decisions regarding fertility-sparing surgery, treatment of infertility or premature hormonal deprivation, intra- and postoperative morbidity, and adjuvant chemotherapeutic treatments are particularly pertinent.

Disclosures In relation to this study, I declare that there are no conflicts of interest.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.